Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Juan Graham is Chief Financial Officer at Perspective Therapeutics. OQRO lists 1 transaction filed with the SEC under this name, the latest on Apr 1, 2025, each linked to the official Form 4.
Chief Financial Officer
Disclosures on record
1
Companies involved
1
1 buy, median +50.6 pts vs S&P 500, beat it 1 of 1 time.
Average +50.6 pts vs S&P 500. Each buy is one disclosure of open-market purchases in one company on one filing date, filed Apr 1, 2025 to Apr 1, 2025, measured from the first close after the filing. Past results, not a forecast.
1 purchase disclosed; 100% of the 1 measured at 90 days finished ahead of the index.
Not ranked: fewer than 10 purchases measured at 90 days. The middle of the 82 ranked insiders is −5.5 pts (median, against the S&P 500).
Mar 28, 2025Bought~$75Kdisclosed Apr 1
DetailsOfficial recordEqual weight counts every purchase once; by size counts it for its disclosed dollars. Both are measured from the first close after it was reported. Past results describe the past, not a forecast. How this is measured · Leaderboard
As of the latest filing on , Juan Graham reported holding 35,354 shares of Perspective Therapeutics (CATX), worth about $33K at the last close of $1 (Nov 13, 2026).
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Perspective Therapeutics CATX | 35,354 | 35K direct | $1 | $33K | Mar 28, 2025 |
Is this Juan Graham’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
Juan Graham bought shares on the open market in 2025 across 2 companies. Sales in 2 of the 5 years since 2022.
Juan Graham reported 1 open-market purchase and 11 sales since 2022; purchases in 2025.
| Year | Bought | Sold |
|---|---|---|
| 2025 | $75K1×1 trade | — |
| 2023 | — | $188K6×6 trades |
| 2022 | — | $129K5×5 trades |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
On the latest SEC Form 4, dated Mar 28, 2025, Juan Graham reported holding 35,354 shares of Perspective Therapeutics (CATX). At the last close of $1 on Nov 13, 2026, that is about $33K. This is the stake disclosed in filings, not a net worth.
Juan Graham bought shares on the open market in 2025 across 2 companies. Sales in 2 of the 5 years since 2022.
In SEC filings since 2022: the latest open-market purchase is from 2025; the latest open-market sale is from 2023.
2 companies: Perspective Therapeutics (CATX, 2025), Kyntra Bio (KYNB, 2022–2023).
Juan Graham reported 0 open-market purchases and 11 sales here, 2022 to 2023.
Juan Graham reported 1 open-market purchase and 0 sales here, 2025.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.
